Because 66 to 70% of NPC tumors overexpress FGF1/2 based on their gene expression, it is possible that a significant proportion of NPC tumors will show sensitivity to FGFR inhibition. This evidence concerns the gene FGF1 and nasopharyngeal carcinoma.